Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Published:2019-01 Issue:1 Volume:20 Page:43-56
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moreno Carol,Greil Richard,Demirkan Fatih,Tedeschi Alessandra,Anz Bertrand,Larratt Loree,Simkovic Martin,Samoilova Olga,Novak Jan,Ben-Yehuda Dina,Strugov Vladimir,Gill Devinder,Gribben John G,Hsu Emily,Lih Chih-Jian,Zhou Cathy,Clow Fong,James Danelle F,Styles Lori,Flinn Ian W

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

3. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience;O'Brien;Blood,2018

4. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Eichhorst;Ann Oncol,2015

5. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

Cited by 468 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy;The Oncologist;2024-09-08

2. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

3. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

4. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-09